Nektar Therapeutics prices $325 million public offering: The Bay Area biotech is selling about 3.5 million shares of stock at $92 per share. The proceeds

Sanofi CEO Paul Hudson bet big on immunology. When Belén Garijo takes over as CEO next week, she will have to decide whether to continue

RIPK1 is becoming a relative desert for large drugmakers. Eli Lilly has joined the exodus, ripping apart the remainder of its up to $960 million

The first recipients of the UK government’s £500 million Sovereign AI fund have been announced, including two life sciences-focused start-ups.

The FDA has extended its review of a new version of Sanofi’s multiple myeloma Sarclisa that could help narrow the gap with arch-rival Darzalex.